• Mitomycin C in Cancer Research: Antitumor Antibiotic & DN...

  2025-10-20

  Mitomycin C stands at the forefront of cancer research as a DNA synthesis inhibitor and TRAIL-induced apoptosis potentiator, uniquely enabling studies in both p53-dependent and independent pathways. This guide delivers actionable workflows, advanced applications, and troubleshooting insights to maximize reproducibility and impact in apoptosis signaling and chemotherapeutic sensitization models.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Prote...

  2025-10-19

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) empowers researchers to safeguard labile protein complexes during plant and mammalian protein extraction, particularly where divalent cation preservation and phosphorylation integrity are paramount. Its advanced formulation, featuring AEBSF, E-64, Leupeptin, Bestatin, and Pepstatin A, is purpose-built for workflows like Western blotting and co-immunoprecipitation—delivering unmatched compatibility and reproducibility in even the most demanding biochemical protocols.

• Beyond Vascular Disruption: DMXAA (Vadimezan, AS-1404) as...

  2025-10-18

  This thought-leadership article explores the mechanistic and translational potential of DMXAA (Vadimezan, AS-1404) not only as a vascular disrupting agent but as a unique modulator of tumor endothelial biology and immune signaling. By synthesizing recent insights into the STING-JAK1 axis and integrating cutting-edge research, we provide strategic guidance for translational researchers on leveraging DMXAA for advanced cancer biology studies, highlighting its role in tumor vasculature normalization and antitumor immune activation.

243 records 17/17 page Previous First page 上5页 1617